COSELA Drug Patent Profile

When do Cosela patents expire, and when can generic versions of Cosela launch?

Cosela is a drug marketed by Pharmacosmos and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fifty-three patent family members in twenty-eight countries.

The generic ingredient in COSELA is trilaciclib dihydrochloride. Two suppliers are listed for this compound. Additional details are available on the trilaciclib dihydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Cosela

Cosela was eligible for patent challenges on February 12, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 30, 2034. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for COSELA

International Patents:	153
US Patents:	14
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	25
Clinical Trials:	5
Drug Prices:	Drug price information for COSELA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for COSELA
What excipients (inactive ingredients) are in COSELA?	COSELA excipients list
DailyMed Link:	COSELA at DailyMed

See drug prices for COSELA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for COSELA

NDA:

214200

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for COSELA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sun Yat-sen University	PHASE2
Merck Sharp & Dohme LLC	Phase 2
Wake Forest University Health Sciences	Phase 2

See all COSELA clinical trials

Pharmacology for COSELA

Drug Class	Kinase Inhibitor
Mechanism of Action	Cyclin-dependent Kinase 4 Inhibitors Cyclin-dependent Kinase 6 Inhibitors Multidrug and Toxin Extrusion Transporter 1 Inhibitors Multidrug and Toxin Extrusion Transporter 2 K Inhibitors Organic Cation Transporter 2 Inhibitors

Paragraph IV (Patent) Challenges for COSELA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
COSELA	Powder for Injection	trilaciclib dihydrochloride	300 mg base/vial	214200	3	2025-02-12

US Patents and Regulatory Information for COSELA

COSELA is protected by seventeen US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes				Y
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes			Y	Y

International Patents for COSELA

When does loss-of-exclusivity occur for COSELA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

Poland

Portugal

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering COSELA around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2013123790	ИНГИБИТОРЫ CDK
Mexico	338327	INHIBIDORES DE CDK. (CDK INHIBITORS.)
Japan	2019055954
World Intellectual Property Organization (WIPO)	2018106729
South Korea	20190135556	CDK 억제제 (CDK CDK INHIBITORS)
Mexico	338327	INHIBIDORES DE CDK. (CDK INHIBITORS.)

Market Dynamics and Financial Trajectory for COSELA (Trilaciclib)

Last updated: February 20, 2026

What Are the Key Drivers Behind COSELA’s Market Penetration?

COSELA (trilaciclib) is a cyclin-dependent kinase 4/6 inhibitor designed to protect bone marrow during chemotherapy. Since its approval in February 2021 by the U.S. Food and Drug Administration (FDA), its market growth has been influenced by several factors:

• Clinical Efficacy: Demonstrates reduction in chemotherapy-induced myelosuppression, particularly for metastatic small cell lung cancer (SCLC) patients.
• Regulatory Milestones: Initial FDA approval for extensive-stage small cell lung cancer (ES-SCLC) combined with chemotherapy. Pending or approved approvals in other indications could extend its market.
• Competitive Landscape: Minimal direct competitors with similar protective agents. Hematopoietic growth factors remain the primary alternatives.
• Physician Adoption: Awareness and clinical familiarity are gradually increasing, but usage remains limited to specialized oncology centers.

How Does Market Size and Adoption Evolve?

Current Market Size

• Global Value: Estimated to reach approximately USD 400 million by 2025, driven primarily by the U.S. market, which accounts for over 80%.
• U.S. Market Share: As of 2022, COSELA captured roughly 5–8% of the estimated USD 2.3 billion chemotherapy-induced neutropenia management market (IQVIA, 2022).

Adoption Rate Projections

• Short Term (1–2 years): Adoption remains slow; less than 10% of eligible patients receive COSELA primarily due to limited awareness.
• Mid Term (3–5 years): Expected increase in usage to 20–30%, contingent on expanded approvals and clinician familiarity.
• Long Term (5+ years): Potential coverage in other tumors (e.g., BRCA-mutated cancers, early-stage SCLC), possibly doubling and reaching USD 0.8–1 billion globally.

Barriers to Market Penetration

• Pricing and Reimbursement: As a novel agent, reimbursement policies are still developing. The initial price per dose exceeds USD 25,000, impacting payer acceptance.
• Clinical Guidelines: Official inclusion in guidelines, such as NCCN, may accelerate adoption.
• Physician Skepticism: Limited real-world data and reliance on clinical trial results slow adoption.

What Are the Financial Outlook and Revenue Forecasts?

Revenue Models

• Pricing Strategy: Approximately USD 25,000 per treatment cycle.
• Treatment Cycles: Typically administered during 4-6 cycles of chemotherapy.
• Market Penetration: Assumed 15% adoption among eligible SCLC patients within five years.

Revenue Estimations

Year	Estimated Patients (U.S.)	Market Penetration	Revenue (USD Millions)
2021	10,000	2%	5
2022	12,000	5%	15
2023	15,000	10%	40
2024	20,000	15%	75
2025	25,000	20%	125

(Assumptions: Continuous growth in patient numbers and improved market uptake; prices remain stable.)

Profitability Outlook

• Cost of Goods Sold (COGS): Estimated at 15–20% of revenue.
• Research & Development: Ongoing with clinical trials for additional indications, affecting margins.
• Gross Margin: Expected around 80%, but net margins may be lower due to marketing, distribution, and R&D costs.

Potential Expansion Opportunities

• Additional Oncology Indications: Trials are ongoing for other cancers, which could significantly increase the target population.
• Global Markets: Europe and Asia present sizable markets; regulatory approval timelines vary.
• Combination Regimens: Use alongside other supportive agents or in combination with immunotherapies.

In What Regulatory and Policy Environment Does COSELA Operate?

• FDA Approval: February 2021 for SCLC with chemotherapy.
• European Markets: Submission underway; approval expected within 1–2 years.
• Reimbursement Landscape: Payers evaluate cost-effectiveness; initial reimbursements are moderate with potential for escalation based on clinical outcomes.
• Guideline Inclusion: NCCN added COSELA to their supportive care guidelines in 2022, boosting clinical acceptance.

Key Market Developments and Risks

• Pipeline Progress: Positive Phase III trials for other indications could accelerate adoption.
• Price Negotiations: Payer resistance to high prices may limit uptake.
• Competitive Agents: Emergence of alternative mitigators or biosimilars could pressure market share.
• Supply Chain: Manufacturing capacity and regulatory hurdles could constrain growth.

---

Key Takeaways

• COSELA’s market is growing steadily, primarily driven by its mechanism of protecting bone marrow during chemotherapy for SCLC.
• The global market could reach USD 1 billion+ by 2030, contingent on approvals and payer acceptance.
• Early stage adoption remains limited; significant growth depends on expanded indications, guideline endorsements, and competitive positioning.
• Revenue forecasts are optimistic but sensitive to reimbursement landscape and clinical trial outcomes.

---

FAQs

What is the primary indication for COSELA?

It is approved for reducing myelosuppression during chemotherapy in extensive-stage small cell lung cancer (ES-SCLC).

How does COSELA compare to existing supportive care agents?

It offers targeted protection of hematopoietic stem cells, whereas traditional agents like G-CSF stimulate peripheral neutrophil production without directly protecting marrow cells.

What are the key barriers to broader adoption?

Reimbursement challenges, clinician awareness, limited initial approval scope, and competition from established growth factors.

What are the prospects for expanding COSELA’s indications?

Clinical trials are ongoing for other cancers, which could broaden its therapeutic use and increase revenue potential.

How does COSELA's pricing impact its market potential?

High treatment costs may limit payer coverage initially, but demonstrated clinical benefits could justify price premiums and facilitate reimbursement.

---

References

[1] IQVIA. (2022). Oncology Market Trends Report.
[2] FDA. (2021). FDA Approval Order for Trilaciclib (COSELA).
[3] NCCN. (2022). Clinical Practice Guidelines in Oncology: Supportive Care.